Cancer Research Technology (CRT) facilitates cancer therapeutic development and commercialization. It has 4 affiliates and funds over 30 projects annually through its £15.5 million investment portfolio. CRT seeks to license its 33 available projects and has successfully developed 4 marketed cancer drugs, with 5 more in clinical trials. It obtains funding from royalty revenues and licensing deals with pharmaceutical partners to reinvest over £95 million annually into its startup and project pipeline.

1. Inception Date: 2002 (CRT), 2005 (CRT-DL), 2006 (CDP and CRT Inc.),
2008 (CTx)
Investment Size: £15.5m annually (2 year avg.)
Products in Market: 4
Products in Clinical Pipeline: 14
Products in Pre-Clinical Pipeline: 6
Currently Funded Startups: 10 (2014)
Projects Available for Licensing/Co-Development: 33
Overview
Cancer Research Technology (CRT) is a specialist commercialization and development company which facilitates the discovery, development
and marketing of new cancer therapeutics, vaccines, diagnostics, and enabling technologies. CRT is a wholly owned subsidiary of Cancer
Research UK (CRUK), the largest independent funder of cancer research in the world.
CRT has since developed 4 affiliates: (1) CRT Discovery Laboratories (CRT-DL), an industrial-focused arm of small molecule drug discovery.
(2) Clinical Development Program (CDP), specializing in therapeutics that have been de-prioritized by pharma and biotech companies.
(3) Cancer Research Technology Inc (CRT Inc.), a U.S. base of CRT focusing on cancer therapeutics development outside of United Kingdom.
(4) Cancer Therapeutics CRC (CTx) a public/private discovery alliance for cancer therapeutics based in Australia.
Cancer Research Technology
Investment Pipeline
• CRT provides project development, small molecule drug discovery, technology commercialization, cancer diagnostics discovery, as well as
clinical development services and funding primarily to more than 30 CRUK affiliated institutes.
• In 2014, CRUK granted £201m in funding to pipeline institutions, the largest benefactor (19.6%) was the University of Cambridge.
Key Facts
Sources of Funding
Sources of Funding
• CRT’s sources of funding are through royalty payments from drug sales— including Temodal, Zytiga, Erivedge, and Lynparza, licensing/co-
development agreements with pharmaceutical companies, ordinary activities (non-royalty income), and income from CRUK.
• In 2014, CRT reported £95m in multi-year funding commitments to CRT affiliated startups, licensed projects, and the CRT Pioneer Fund.
CRUK and CRT Pipeline
Cancer Research UK Annual Report and Accounts 2013/2014
CRUK Institutes
CRUK Centres
Clinical Trial Sites
0
20
40
60
80
100
2014 2013
£millions
CRUK Charitable Income
Royalties
Ordinary Activities
CRT Pioneer Fund Contributions
Licensing/Partnerships*
Cancer Research UK Annual Report and Accounts 2013/2014
*Based on publically disclosed values only.

2. Track Record
• CRT funding has allowed for the development of 4 cancer therapies that have since entered market: Temodal, Zytiga, Erivedge, and Lynparza.
• In 2015, 5 CRT funded drugs were in Phase-II or III of clinical testing: Rucaparib, TG4010, HSP90, SG2000, and Akt/PKB.
Exits
• The CRT Pioneer Fund seeks exit at Phase II of clinical trials through partnership agreements with pharmaceutical and biotechnology
companies. Current pharmaceutical partners include: Merck, J&J, Roche, AstraZeneca, Amgen, Genentech, GSK, etc.
• CRT actively seeks to license and co-develop projects in their portfolio with 33 projects available for licensing currently. In 2014, CRT
received £68m from licensing fees, up 37% from 2013 figures (£50m).
• Since it’s inception, CRT has cumulatively returned more than £50m back to CRUK initiatives.
Key Initiatives
Investment Structure
• CRT invests directly into their pipeline through two means: (1) CRT Pioneer Fund and (2) CRT Project Development Fund.
• The CRT Pioneer Fund is a £70m Fund dedicated to investment in oncology development programmes in Europe. The sweet spot for
investment is pre-lead optimization through to early clinical trials. The Fund is dedicated to asset financing projects from Europe and
expects to commit two-thirds of its investment to projects derived from Cancer Research UK oncology drug discovery portfolio with
the remainder being invested in projects from outside Cancer Research UK. The fund is managed by Sixth Element Capital LLP.
• The CRT Project Development Fund provides minor bridge funding for projects to progress between different stages of clinical
development. In 2012/13, the Fund leveraged £14m in industry funding across 22 projects.
Cancer Research Technology Press Releases
Cancer Research Technology
CRT Project Development (2014)
Cancer Research Technology 2014 Year in Review
= 10
Scientists Visited Deals Completed
Patents Filed Projects Funded
CRT launches Ximbio,
an online reagents
portal for the life
science community.
Apr2014
CRT Pioneer Fund banks
£20m investment from
BACIT as company joins as
limited partner.
Nov 2015
CRT and Nuevolution
sign multi-target deal
for cancer therapies.
Sept2013 Mar
CRT and Janssen enter
collaboration for new
multiple myeloma drug. $